Skip to main content
Caplight Logo









Priavoid

Priavoid

Private
DusseldorfHealthcare & Life Scienceshttps://priavoid.com/

Last Round

Grant

Oct 1, 2024

Total Funding Raised

$8.47M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Priavoid is a biopharmaceutical company developing a novel class of orally available all-D-peptide therapeutics to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

all-d-peptide therapeuticsneurodegenerative disordersAlzheimer's diseaseoligomer detanglertoxic protein oligomersdisease-modifying treatmentclinical-stage biopharmadrug discovery platformamyloid-betaorally available drugParkinson's diseasepeptide therapeuticsprotein misfolding diseasesalpha-synucleintauopathiesblood-brain barrier

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Priavoid Comparables

Compare Priavoid with similar companies based on industry and business-model similarity.

Priavoid comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Acumen Pharmaceuticals
78%
AC Immune SA
78%
Alzinova
77%

Priavoid Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 1, 2024
Series AFeb 12, 2021

Key People

Founding team and executive leadership

Philipp Bürling

CEO

Executive Team

Priavoid Investors

Notable investors and investment history

Priavoid investors
InvestorRounds
Rainwater Charitable FoundationGrant
Alzheimer's AssociationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 23, 2026

    Grew 17% QoQ, from 18 to 21 employees.

  • Jul 20, 2026

    Open roles increased to 4, representing 21% of headcount.

Priavoid Filings

Explore SEC and related filing metadata, where available.

Priavoid filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Priavoid's valuation, stock price, and market status.

Is Priavoid a public or private company?

Priavoid is a private company.

What is the current stock price of Priavoid?

Priavoid is a private company with no public stock price. No recent secondary market data is available.

How much is Priavoid worth (valuation)?

Valuation information for Priavoid is not publicly available.

Can I buy Priavoid stock?

Priavoid shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Priavoid's last funding round?

Priavoid's most recent funding round was Grant on October 1, 2024.

Who are the main investors in Priavoid?

Key investors in Priavoid include Rainwater Charitable Foundation, Alzheimer's Association.

Will Priavoid IPO soon?

No public IPO plans have been announced for Priavoid.

How can I track Priavoid secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Priavoid's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDusseldorf
Employee Range14
Year Founded2017
Last FundingOct 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?